Stockscreener 앱 받기
5.14
2.80%
0.14
전일 마감가:
$5.00
열려 있는:
$5
하루 거래량:
8.08M
Relative Volume:
1.56
시가총액:
$1.37B
수익:
-
순이익/손실:
$-252.18M
주가수익비율:
-4.8491
EPS:
-1.06
순현금흐름:
$-185.29M
1주 성능:
+0.19%
1개월 성능:
+26.60%
6개월 성능:
+102.36%
1년 성능:
+151.96%
1일 변동 폭
$4.865
$5.35
1주일 범위
$4.252
$5.427
52주 변동 폭
$1.26
$7.30
사나 바이오테크놀로지 Stock (SANA) Company Profile
명칭
Sana Biotechnology Inc
전화
(206) 701-7914
주소
188 EAST BLAINE STREET, SUITE 400, SEATTLE
SANA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
5.14 | 1.33B | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
사나 바이오테크놀로지 Stock (SANA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | Wedbush | Outperform |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-03-18 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-01-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-11-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | 개시 | Rodman & Renshaw | Buy |
| 2024-01-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-08-14 | 개시 | TD Cowen | Market Perform |
| 2023-05-02 | 개시 | H.C. Wainwright | Neutral |
| 2021-03-01 | 개시 | BofA Securities | Buy |
| 2021-03-01 | 개시 | Goldman | Neutral |
| 2021-03-01 | 개시 | JP Morgan | Neutral |
| 2021-03-01 | 개시 | Morgan Stanley | Overweight |
모두보기
사나 바이오테크놀로지 주식(SANA)의 최신 뉴스
Sana Biotechnology Reports Reduced Losses and Strong Liquidity - MSN
Sana Biotechnology (SANA): Valuation Check After New In Vivo Gene Editing Data in Nature Biotechnology - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Sana Biotechnology Stock: Soar or Sputter? - StocksToTrade
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.9%Time to Sell? - MarketBeat
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform - The Manila Times
Sana Biotechnology Announces Publication in Nature - GlobeNewswire
Buyout Rumor: How Sana Biotechnology Inc stock performs in weak economyNew Guidance & Daily Profit Maximizing Trade Tips - moha.gov.vn
Sana (SANA) Surges 14.5% Ahead of Business Announcements - MSN
Is Sana Biotechnology's (SANA) SC451 Pivot Quietly Redefining Its Long-Term Platform Strategy? - simplywall.st
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation - Quantisnow
Sana Biotechnology’s Surging Stock: Buy or Sell? - StocksToTrade
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Sana Biotechnology (NASDAQ:SANA) Trading Up 6.6%Should You Buy? - MarketBeat
Sana Biotechnology (SANA) Stock Analysis Report | Financials & Insights - Benzinga
Will Sana Biotechnology’s (SANA) Pipeline Focus Reveal Strategic Priorities in Diabetes and Autoimmune Innovation? - Yahoo Finance
Sana Biotechnology Beats Earnings Estimates, Prioritizes SC451 and CAR T - StocksToTrade
Sana Biotechnology Surges Amid Strong Q3 Earnings Performance - timothysykes.com
Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains - Yahoo Finance
Sana Biotechnology (SANA): Evaluating Valuation After Recent Surge in Share Price - Sahm
10 Small Stocks with Mighty Gains - Insider Monkey
Sana Biotechnology (NASDAQ:SANA) Trading 12.8% HigherStill a Buy? - MarketBeat
Sana Biotechnology to Present at December 2025 Investor Conferences - GlobeNewswire
Sana Biotechnology, Inc. to Webcast Presentations at December Investor Conferences - Quiver Quantitative
Sana Biotechnology (NASDAQ: SANA) to Present at 2025 Citi and Evercore Conferences - Stock Titan
Sana Biotechnology (NASDAQ:SANA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Citi Maintained a Buy Rating on Sana Biotechnology (SANA) - MSN
Why Sana Biotechnology Inc. stock could benefit from AI revolutionWatch List & Fast Gaining Stock Strategy Reports - newser.com
Can Sana Biotechnology Inc. stock deliver surprise earnings beat2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
How Sana Biotechnology Inc. stock benefits from global expansion2025 Biggest Moves & Free Reliable Trade Execution Plans - newser.com
Evaluating Sana Biotechnology Inc. with trendline analysisJuly 2025 Sentiment & Expert Curated Trade Ideas - newser.com
What valuation multiples suggest for Sana Biotechnology Inc. stock2025 Big Picture & Free AI Powered Buy and Sell Recommendations - newser.com
Using Ichimoku Cloud for Sana Biotechnology Inc. technicalsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Will Sana Biotechnology Inc. stock benefit from automationBull Run & Daily Risk Controlled Trade Plans - newser.com
The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care - Markets Financial Content
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sana Biotechnology (SANA) Wins Analyst Support With Strategic Focus and Cash Strength - Insider Monkey
Top 3 Genomics Stocks to Consider for Your Portfolio - Nasdaq
Can Sana Biotechnology Inc. recover in the next quarterTreasury Yields & Fast Exit and Entry Trade Guides - newser.com
사나 바이오테크놀로지 (SANA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사나 바이오테크놀로지 주식 (SANA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wyrick Susan D. | See Remarks |
Jun 03 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
170,395 |
| Wyrick Susan D. | See Remarks |
Mar 07 '25 |
Option Exercise |
0.00 |
3,250 |
0 |
158,231 |
| Cassidy Bernard J | EVP & General Counsel |
Mar 07 '25 |
Option Exercise |
0.00 |
11,041 |
0 |
115,823 |
| Harr Steve | President & CEO |
Mar 07 '25 |
Option Exercise |
0.00 |
50,000 |
0 |
7,889,750 |
| Wyrick Susan D. | See Remarks |
Mar 02 '25 |
Option Exercise |
0.00 |
1,525 |
0 |
155,471 |
1.08%
0.91%
자본화:
|
볼륨(24시간):